A surge in the use of non-FDA-approved, compounded, and counterfeit versions of diabetes and obesity drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) has prompted warnings from the FDA and leading medical organizations due to serious safety concerns. Initially allowed during drug shortages, compounded forms will soon be banned as shortages have officially ended. Experts emphasize that these unregulated alternatives—often sold by questionable online sources—lack the rigorous testing and oversight of FDA-approved medications.
Keep Reading
Add A Comment